05:17 PM EST, 01/21/2025 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) said late Tuesday it appointed Naji Gehchan as chief medical and development officer.

Gehchan most recently served as the head of clinical development for the imlunestrant breast cancer treatment at Eli Lilly (LLY).

Shares of Kyverna Therapeutics ( KYTX ) were up 3% in after-hours trading.